Human T cell leukemia virus type 1, the first human retrovirus ever identified, infects an estimated 5 to 10 million people worldwide, a figure extrapolated from surveys covering only about one-seventh of the global population. The virus inserts a DNA copy of its RNA genome into the chromosomes of host T cells, establishing a lifelong infection that can drive a spectrum of diseases, including adult T cell leukemia/lymphoma, HTLV-1-associated myelopathy, and HTLV-1-associated uveitis, a chronic inflammation inside the eye that is particularly common in endemic regions such as Japan. Despite the scale of the problem, coordinated global action has been slow; the World Health Organization only published technical reports aimed at reducing HTLV-1-related morbidity and mortality in 2021, and no broadly effective intervention has emerged in decades of research.

Current treatment for the ocular disease relies heavily on corticosteroids, delivered as topical drops, injections into the eye, or oral prednisone. This approach has serious shortcomings. Studies indicate that 30 to 60 percent of patients with HTLV-1-associated uveitis experience recurrent episodes, and long-term steroid exposure can trigger cataracts, glaucoma, macular edema, epiretinal membranes, retinal degeneration, optic nerve atrophy, and bullous keratopathy. Most importantly, corticosteroids suppress inflammation without reducing the number of virus-infected cells or halting disease progression. Newer molecular targeted agents, including the anti-CCR4 antibody mogamulizumab and the immunomodulatory drug lenalidomide, have been explored, but treatment-related inflammation and adverse effects remain significant obstacles. This therapeutic gap motivated a team led by Yaru Zou and Koju Kamoi of Tokyo Medical and Dental University to investigate whether an epigenetic drug already approved for blood cancer could address the root of the ocular inflammation.

The drug in question is valemetostat, marketed as EZHARMIA, a dual inhibitor of the enzymes EZH1 and EZH2 that was approved in 2022 for adult T cell leukemia/lymphoma. Both enzymes are the catalytic components of polycomb repressive complex 2, a molecular machine that silences genes by adding three methyl groups to lysine 27 on histone H3, producing the repressive chromatin mark known as H3K27me3. Previous work had shown that EZH1 and EZH2 are overexpressed, and H3K27me3 deposition increased, in ATL cells and in cells expressing the viral oncoprotein Tax. Dual EZH1/2 inhibitors have also been reported to curb the spontaneous proliferation and exaggerated immune responses of HTLV-1-infected cells in patients with HTLV-1-associated myelopathy. What remained unknown was whether such inhibition could benefit the inflamed eye.

To find out, the researchers built a series of laboratory models centered on ARPE-19 cells, a human retinal pigment epithelial cell line chosen because the retinal pigment epithelium forms the outer blood-retinal barrier and governs retinal immune homeostasis. They exposed these ocular cells to three kinds of T cells: MT-2 cells, which carry transcriptionally active HTLV-1 and express the viral protein Tax; TL-Om1 cells, an ATL-derived line in which the virus is largely silent and Tax is low or absent; and Jurkat cells, which are uninfected and served as controls. In parallel, they treated the T cell lines themselves. Western blotting and quantitative PCR revealed that HTLV-1 infection drove significant upregulation of both EZH1 and EZH2, along with elevated H3K27me3, in infected retinal pigment epithelial cells and in MT-2 cells, with EZH1 protein rising roughly 2.5-fold in infected ocular cells and six-fold in MT-2 cells. This was the first demonstration that HTLV-1 infection induces polycomb-mediated epigenetic changes in retinal cells.

The team then treated the models with valemetostat at 0.01, 0.1, and 1 micromolar for 96 hours, concentrations selected in preliminary experiments because they harmed infected T cells while leaving normal ocular cells, including primary human trabecular meshwork cells, unaffected below 10 micromolar. The results were strikingly dependent on the model. In co-cultures of retinal cells with Tax-positive MT-2 cells, and in retinal cells directly infected with HTLV-1, the drug produced modest but statistically significant reductions in cell viability at the highest dose, accompanied by small increases in late-stage apoptosis. No such effects appeared in co-cultures with TL-Om1 or Jurkat cells. Crucially, the absolute magnitude of apoptosis remained limited, typically only 1 to 3 percent above baseline, indicating that valemetostat is not broadly toxic to retinal cells, an important safety consideration given their role in maintaining vision.

The virological findings were equally nuanced. Valemetostat did not significantly reduce the HTLV-1 proviral load in co-culture systems or in directly infected retinal pigment epithelial cells. However, in MT-2 cells themselves, 1 micromolar valemetostat significantly lowered proviral load and suppressed the messenger RNA levels of both Tax and HBZ, the two hallmark transcripts of the virus. Because MT-2 cells represent the transcriptionally active, highly infectious state of HTLV-1, while TL-Om1 represents latency, the results suggest that the drug’s antiviral effect is gated by the transcriptional status of the infected cell. Within the four-day treatment window, the authors conclude, valemetostat’s benefit to the ocular environment is likely indirect, acting primarily by quieting the most virally active cells rather than by eradicating provirus everywhere.

The most clinically relevant effects emerged in the inflammatory readouts. HTLV-1-infected T cells recovered from the eyes of patients with uveitis are known to secrete copious interleukin-6, interleukin-8, and interleukin-10, all implicated in disease. In the new study, valemetostat produced a dose-dependent increase in the anti-inflammatory cytokine IL-10 in MT-2-containing conditions, significant at 1 micromolar in the co-culture system and across all doses in MT-2 cells. This fits a mechanistic expectation: blocking EZH1/2 removes H3K27me3 marks that repress the IL-10 gene, and prior genetic studies showed that loss of EZH2 directly activates IL-10 transcription in several CD4-positive T cell subsets. Meanwhile, pro-inflammatory signals fell in a context-dependent pattern. IL-12p70 and the chemokine CXCL-10 dropped in co-cultures, IL-6 and IL-8 declined mainly in MT-2 cells, and CCL-2 fell at low doses in the MT-2 co-culture, whereas the chemokine CCL-5 was unchanged in every model.

The drug’s influence on NF-kappaB, the central inflammatory pathway that Tax hijacks to drive both viral replication and cytokine production, was more subdued. Valemetostat modestly reduced NF-kappaB p65 phosphorylation in the MT-2 co-culture at the lowest dose and slightly decreased the nuclear-to-cytoplasmic ratio of p65 in retinal cells stimulated with TNF-alpha, but it did not abolish nuclear translocation. The authors attribute this to the overwhelming strength of Tax-driven NF-kappaB activation, which a 96-hour course of EZH1/2 inhibition may be insufficient to counteract, and to the fact that NF-kappaB and cytokine networks are regulated by many factors beyond polycomb complexes. Immunofluorescence confirmed that valemetostat significantly lowered H3K27me3 in retinal cells exposed to MT-2 cells or directly infected, but not in cells co-cultured with TL-Om1 or Jurkat cells, again underscoring the model dependence of the epigenetic response.

The study also carries a cautionary note about IL-10. Although the cytokine is anti-inflammatory, it can promote the survival of HTLV-1-infected T cells and facilitate immune evasion by impairing dendritic cell antigen presentation and downregulating MHC class I molecules, and patients with aggressive ATL often show abnormally elevated IL-10. The authors therefore suggest that combining EZH1/2 inhibition with IL-10 pathway blockade could prove more effective, noting evidence that IL-10 neutralization sensitizes ATL cells to standard therapies. In the TL-Om1 model of ATL-related ocular infiltration, valemetostat failed to reduce H3K27me3, proviral load, or NF-kappaB activation within the malignant cells, yet it suppressed TL-Om1-induced CXCL10 secretion and induced dose-dependent apoptosis, pointing to a benefit mediated through the inflammatory microenvironment rather than direct tumor killing.

The authors are candid about the limitations. The work relied entirely on in vitro co-cultures and established cell lines, which cannot reproduce the blood-retinal barrier, retinal architecture, or local immune regulation of a living eye, and the intraocular pharmacokinetics of valemetostat after systemic administration remain undefined. Sex as a biological variable could not be assessed because donor-defined primary cells were not used. Even so, the findings establish a proof of concept that an approved epigenetic therapy can counteract HTLV-1-induced chromatin changes in retinal cells, dampen viral transcription in the most active infected cells, and reshape the cytokine milieu that sustains uveitis. Longer treatment studies, in vivo models, and patient-derived systems will be needed to determine whether these modest, context-dependent effects can be translated into a genuine steroid-sparing therapy for one of the most burdensome manifestations of a virus that medicine has long neglected.

Subject of Research: EZH1/2-targeted epigenetic therapy with valemetostat for HTLV-1-associated uveitis

Article Title: Dual impact of EZH1/2-targeted therapy in HTLV-1-associated inflammation: Direct and indirect mechanisms

Article References: Zou, Y., Kamoi, K., Yang, M., Zong, Y., Zhang, J., & Ohno-Matsui, K. (2026). Dual impact of EZH1/2-targeted therapy in HTLV-1-associated inflammation: Direct and indirect mechanisms. iScience, 29(11), Article 117775. https://doi.org/10.1016/j.isci.2026.117775

Image Credits: AI Generated

DOI: 10.1016/j.isci.2026.117775

Keywords: HTLV-1, valemetostat, EZH1, EZH2, H3K27me3, uveitis, epigenetics, PRC2, Tax, IL-10, NF-kappaB, retinal pigment epithelium

Palliative care has long been framed as a specialist discipline reserved for hospices and oncology wards, but a growing body of evidence insists it belongs everywhere people approach the end of life, including nursing homes, where a large share of deaths in ageing societies now occur. A new qualitative study from Sweden, published in BMC Nursing, offers an unusually candid look at what happens inside care teams after they receive structured palliative care education, and the central finding is striking: training changes how staff think, but thinking alone does not change care. The researchers, Camilla Ekeblom, Carina Lundh Hagelin and Jane Österlind of Marie Cederschiöld University in Stockholm, found that the value of an educational intervention depends on an intricate alignment between individual emotions, relational dynamics and organisational realities, and that when any one of these dimensions falls out of step, the benefits of education can quietly dissolve.

The study set out to explore how nursing home staff reason about providing palliative care after participating in an interprofessional educational intervention, abbreviated in the literature as IPEI. Rather than measuring outcomes with questionnaires, the team chose a descriptive qualitative design, interviewing eighteen staff members drawn from five Swedish nursing homes. The participants represented the full spectrum of people who actually deliver and manage care: registered nurses, assistant nurses, a physician, first-line managers and designated palliative care champions. This breadth matters, because palliative care in nursing homes is not delivered by any single profession; it emerges, or fails to emerge, from the daily interplay of people with different training levels, responsibilities and emotional exposures to dying residents.

Data were collected through semi-structured individual interviews conducted between March and April 2024, and analysed using inductive qualitative content analysis, a method that allows themes to rise from the material itself rather than being forced into pre-existing theoretical boxes. From this analysis, three main categories emerged, and together they map the terrain on which palliative care is actually practised. The first concerns managing one’s own emotions, thoughts and attitudes. The second addresses the significance of relationships, communication and interactions in care. The third captures how staff navigate norms, assumptions and organisational structures in everyday palliative care. The categories correspond, respectively, to the individual, relational and organisational dimensions of the work, and the authors argue that it is the interplay among all three, not any single factor, that determines whether good palliative care becomes possible.

The individual dimension is perhaps the most human part of the findings. Staff described the ongoing internal work of confronting their own feelings about death, ageing and suffering, and of examining assumptions they carried about what palliative care even means. A recurring tension in the literature, echoed here, is the tendency to equate palliative care narrowly with end-of-life care, the final days and hours, rather than understanding it as an approach that can and should be integrated into everyday care over a longer trajectory. The interviews suggested that the educational intervention gave participants opportunities for personal as well as professional development, creating space to reflect on attitudes that had previously gone unexamined. In this sense, education functioned less like a knowledge transfer and more like a mirror, prompting staff to notice how their own emotional responses shaped their clinical decisions.

The relational dimension proved equally consequential. Palliative care in a nursing home is saturated with communication: conversations with residents about what matters to them, exchanges with distressed relatives, coordination between assistant nurses who know the residents intimately and nurses and physicians who carry clinical responsibility. The participants’ reasoning placed relationships and interactions at the heart of care provision, indicating that no amount of theoretical knowledge substitutes for the ability to build trust, listen and communicate across professional boundaries. This is where the interprofessional design of the intervention appears to have paid off. By bringing different professions into a shared educational space, the programme created a common language and, implicitly, a shared understanding of what the team was trying to achieve together, something that fragmented, profession-specific training often fails to produce.

The third dimension, the organisational, is where the study’s message becomes most uncomfortable for policymakers and care home leadership. Staff described navigating norms and assumptions embedded in their workplaces, along with structural conditions that could either support or obstruct a palliative approach. Staffing levels, routines, leadership priorities and workplace culture all shape what is practically possible on a shift where residents are dying, families are anxious and time is scarce. The authors’ conclusion is explicit on this point: providing palliative care was not solely a matter of enhancing staff knowledge. Knowledge and the conditions for care are shaped through the interplay between staff attitudes, their reasoning about care, relational dynamics and organisational conditions. When these dimensions align and mutually reinforce one another, favourable conditions for palliative care may be supported; when they do not, even well-trained staff may find their intentions frustrated.

Why does this matter on a societal scale? Nursing homes accommodate older people with complex needs and account for a large proportion of deaths, which makes palliative care a central component of care in these settings rather than an occasional emergency. Yet access to palliative care remains unequal, particularly for older people, and staff in long-term care often lack sufficient training. The demographic arithmetic is unforgiving: as populations age, the number of people who will die in nursing homes rises, and the quality of their final months depends heavily on the competence and confidence of the workforce that cares for them. Studies like this one move the conversation beyond the simplistic assumption that a training course fixes the problem, and toward a systems view in which education is necessary but insufficient on its own.

The study also carries a methodological lesson for how we evaluate educational interventions in care settings. Much of the existing research measures knowledge gains or self-reported confidence before and after training. Those metrics are useful, but they cannot reveal how staff actually reason about applying what they have learned in the messy reality of daily care. By using inductive content analysis of interviews, the Swedish team surfaced the texture of that reasoning: the hesitations, the emotional labour, the negotiations with colleagues and managers, the quiet adjustments between ideal practice and what the shift allows. The findings suggest that interprofessional educational initiatives work best when they combine theoretical knowledge with opportunities for reflection and practical application, allowing staff to translate concepts into their own working context rather than leaving translation to chance.

There are limits worth noting. The study involved eighteen participants in five Swedish nursing homes, interviewed at a single point in time after the intervention, and qualitative findings are not designed to be statistically generalised. The researchers themselves submitted the work for ethical review, receiving approval from the Swedish Ethical Review Authority, and obtained written informed consent from all participants, but the transferability of the results to other health systems will depend on how similar those systems’ nursing homes and educational programmes are to the Swedish context. Still, the three-dimensional framework that emerged, individual, relational and organisational, offers a portable lens that other teams can use to examine their own settings, and it aligns with a broader international consensus that palliative care competence must be built at every level of an organisation simultaneously.

The most durable insight from this research may be its refusal to locate the solution in any single place. Staff who completed the intervention perceived it as an opportunity for growth, and their reasoning showed genuine movement in how they understood palliative care as an ongoing approach rather than a final act. But their accounts also made clear that attitudes, relationships and structures must pull in the same direction for that understanding to reach residents’ bedsides. For nursing homes everywhere, the implication is a practical checklist of a different kind: train your staff together, give them room to reflect, examine the norms your workplace quietly enforces, and make sure the organisation’s daily conditions match what the education teaches. Where those elements align, palliative care stops being an aspiration and becomes, simply, the way care is done.

Subject of Research: Nursing home staff's reasoning about providing palliative care after an interprofessional educational intervention

Article Title: “Nursing home staff’s reasoning about providing palliative care following an educational intervention – a qualitative interview study”

Article References: Ekeblom, C., Lundh Hagelin, C., & Österlind, J. (2026). “Nursing home staff’s reasoning about providing palliative care following an educational intervention – a qualitative interview study”. BMC Nursing, 25(1), Article 956. https://doi.org/10.1186/s12912-026-05480-4

Image Credits: AI Generated

DOI: 10.1186/s12912-026-05480-4

Keywords: palliative care, nursing homes, older people, interprofessional education, qualitative research, nursing education, end-of-life care, care staff attitudes, organisational conditions, Sweden, BMC Nursing, healthcare workforce

Nuove analisi digitali di un'antica iscrizione suggeriscono che Meretneith, vissuta circa 5.000 anni fa, potrebbe aver governato l'Egitto come una vera sovrana durante la Prima Dinastia.

Assinantes do Apple TV já podem conferir o primeiro episódio da aguardada sexta temporada de “Slow Horses”, série de espionagem estrelada por Gary Oldman, que retorna hoje.

Aos que nunca deram uma chance para a série, “Slow Horses” acompanha uma equipe de agentes da inteligência britânica, os quais servem em um departamento do MI5 conhecido como Slough House. Oldman assume o papel de Lamb, o brilhante (mas rabugento) líder dos espiões, que acabam indo para a Slough House devido a erros que acabaram com suas carreiras.

Reveja o trailer da sexta temporada a seguir:

A nova parte da produção acompanhará a fuga dessa equipe, enquanto Diana Taverner (interpretada por Kristin Scott Thomas) os envolve em um jogo de retaliação e vingança com riscos e consequências fatais.

Mesmo que a sexta temporada só esteja chegando agora ao Apple TV, já sabemos que “Slow Horses” terá pelo menos mais duas temporadas, já que a Maçã anunciou mais uma renovação adiantada da produção — que tem sido, há anos, uma das mais premiadas do serviço. Nesta semana, inclusive, a série faturou o prêmio de Melhor Direção de Série de Drama (recebido por Saul Metzstein) nos Primetime Emmy Awards 2026.

Além de Scott Thomas e Oldman, o elenco inclui Jack Lowden, Saskia Reeves, Christopher Chung, Rosalind Eleazar, Joanna Scanlan, Samuel West, Ruth Bradley, Hugo Weaving, Lenny Rush, Aimee-Ffion Edwards, James Callis, Tom Brooke, Jonathan Pryce e Olivia Cooke. Oldman também assina a produção executiva, ao lado de Jamie Laurenson, Hakan Kousetta, Julian Stevens, Iain Canning, Emile Sherman, Gail Mutrux, Douglas Urbanski, Gaby Chiappe e Adam Randall, que retorna também à direção.

Alguns desses nomes, vale notar, marcaram presença na première da sexta temporada, organizada pelo Apple TV na última sexta-feira (11/9) no TIFF Lightbox Theater, em Toronto (Canadá):

Como dito, apenas o primeiro dos seis episódios da sexta temporada foi liberado hoje. Os capítulos remanescentes serão disponibilizados semanalmente, às quartas-feiras, até 21 de outubro.

O Apple TV está disponível no aplicativo Apple TV em mais de 100 países e regiões, seja em iPhones, iPads, Apple TVs, Macs, dispositivos Android, smart TVs ou online — além de estar em aparelhos como Roku, Amazon Fire TV, Chromecast com Google TV, consoles PlayStation e Xbox. O serviço custa R$34,90 por mês, com um período de teste gratuito de 7 dias. Por tempo limitado, quem comprar e ativar um novo iPhone, iPad, Apple TV ou Mac ganha 3 meses do Apple TV. Ele também faz parte do pacote de assinaturas da empresa, o Apple One.

NOTA DE TRANSPARÊNCIA: O MacMagazine recebe uma pequena comissão sobre vendas concluídas por meio de links deste post, mas você, como consumidor, não paga nada mais pelos produtos/serviços usando os nossos links de afiliado.

Friday night at the TIFF Lightbox Theater in Toronto, Apple TV celebrated the world premiere of the sixth season of Emmy Award-winning spy series “Slow Horses,” which makes its global debut on Apple TV on September 16, 2026. Red carpet attendees included Sir Gary Oldman, who reunited with stars Olivia Cooke, Saskia Reeves, Christopher Chung, Rosalind Eleazar, Aimee-Ffion Edwards and Ruth Bradley, alongside director and executive producer Adam Randall, executive producers Hakan Kousetta and Douglas Urbanski, and co-executive producer Billy Bowring.

“Slow Horses” is a darkly humorous espionage drama that follows a dysfunctional team of British intelligence agents who serve in a dumping ground department of MI5 known, unaffectionately, as Slough House. Oldman stars as Jackson Lamb, the brilliant but cantankerous leader of the spies who end up in Slough House due to their career-ending mistakes and who frequently find themselves blundering around the smoke and mirrors of the espionage world. Season six sees the Slow Horses on the run as Diana Taverner embroils them all in a fatally high-stakes game of retaliation and revenge.

The ensemble cast includes Academy Award nominee Kristin Scott Thomas, Emmy Award nominee Jack Lowden, Saskia Reeves, BAFTA TV Award nominee Christopher Chung, Aimee-Ffion Edwards, Rosalind Eleazar, Joanna Scanlan, BAFTA Award nominee Samuel West, Ruth Bradley, Tom Brooke, Academy Award nominee Jonathan Pryce and Hugo Weaving, alongside new addition, BAFTA TV Award winner Lenny Rush. Additionally, Olivia Cooke will reprise her role as Sidonie “Sid” Baker in the sixth season.

“Slow Horses” has been celebrated as “undoubtedly the best spy series on television,” a “truly epic espionage thriller” that is “utterly brilliant” and just “so damn good.” All five seasons of “Slow Horses” hold a Certified Fresh score, with two seasons receiving a rare, perfect 100 percent critics’ score on Rotten Tomatoes, and the series continues to receive global accolades from critics and fans alike. The fifth season earned nine Primetime Emmy Awards, including a nod for Outstanding Drama Series, and nominations for Gary Oldman and Jack Lowden in the categories of Outstanding Lead Actor and Outstanding Supporting Actor, respectively.

The series is produced for Apple TV by See-Saw Films, with Jamie Laurenson, Hakan Kousetta, Julian Stevens, Iain Canning, Emile Sherman, Adam Randall, Gail Mutrux, Douglas Urbanski and Oldman serving as executive producers. Season six is adapted for television by co-executive producer Gaby Chiappe, with Randall returning to direct.

Apple TV offers premium, compelling drama and comedy series, feature films, groundbreaking documentaries, and kids and family entertainment, and is available to watch across all of a user’s favorite screens. After its launch on November 1, 2019, Apple TV became the first all-original streaming service to launch around the world, and has premiered more original hits and received more award recognitions faster than any other streaming service in its debut. To date, Apple Original films, documentaries and series have been honored with 913 wins and 3,827 award nominations and counting including multi-Emmy Award-winning and history-making comedies “The Studio” and “Ted Lasso,” global cultural phenomenon “Severance,” Apple’s most-viewed drama “Pluribus,” Academy Award Best Picture winner “CODA” and Academy Award winner “F1,” the highest-grossing sports feature of all time.
‎
MacDailyNews Note: Apple TV is available on the Apple TV app in over 100 countries and regions, on over 1 billion screens, including iPhone, iPad, Apple TV 4K, Apple Vision Pro, Mac, popular smart TVs from Samsung, LG, Sony, VIZIO, TCL and others, Roku and Amazon Fire TV devices, Chromecast with Google TV, PlayStation and Xbox gaming consoles, and at tv.apple.com, for $14.99 per month with a seven-day free trial for new subscribers. For a limited time, customers who purchase and activate a new iPhone, iPad, Apple TV 4K or Mac can enjoy three months of Apple TV for free.

---

‎
Please help support MacDailyNews — and enjoy subscriber-only articles, comments, chat, and more — by subscribing to our Substack: macdailynews.substack.com. Thank you!

Support MacDailyNews at no extra cost to you by using this link to shop at Amazon.

The post Apple TV hosts world premiere for the sixth season of ‘Slow Horses’ at TIFF appeared first on MacDailyNews.

Politeness survives perfectly well without the so-called 'magic word'.

It’s easy to see why people might latch onto the idea of a reptilian brain as an explainer, or an explainaway, for complex topics.

Source

The three Indian companies are accused of using hackers to steal information used to sway litigation.

O elenco de “Disavowed”, vindouro thriller de ação do Apple TV, ganhou mais um nome de peso. Segundo o Deadline, a atriz Sylvia Hoeks — conhecida por seus papéis em “Parceiras no Crime” (“Ride or Die”) e “See” — é a mais nova contratada como membro regular do elenco.

Detalhes sobre a personagem de Hoeks na trama ainda não foram revelados.

Anunciada em maio, a série é estrelada por James Marsden e já havia somado Norman Reedus ao time em agosto. Em “Disavowed”, acompanharemos o lendário agente da CIA Brad Griffin (Marsden) logo após ser demitido abruptamente no meio de uma caçada global a um assassino responsável pela morte de um colega. Marginalizado no mundo da inteligência, o protagonista decide ir atrás da recompensa de US$15 milhões pelo assassino.

Hoeks é reconhecida internacionalmente por seu papel como Luv em “Blade Runner 2049” e também esteve no elenco de “See”, outra produção do Apple TV, como a Rainha Kane.

“Disavowed” é uma criação original e o primeiro projeto televisivo da dupla formada por Art Marcum e Matt Holloway. Eles também serão produtores executivos ao lado de Marsden, Tom Spezialy, Michelle MacLaren e Rebecca Hobbs. MacLaren, de “The Morning Show” e “Breaking Bad”, dirigirá os dois primeiros episódios.

A Blue Marble Pictures — responsável por “Pachinko” — produzirá a série em conjunto com o Apple Studios, com Theresa Kang e Caroline Garity também como produtoras executivas.

“Disavowed” ainda não possui uma data de estreia confirmada.

O Apple TV está disponível no aplicativo Apple TV em mais de 100 países e regiões, seja em iPhones, iPads, Apple TVs, Macs, dispositivos Android, smart TVs ou online — além de também estar em aparelhos como Roku, Amazon Fire TV, Chromecast com Google TV, consoles PlayStation e Xbox. O serviço custa R$34,90 por mês, com um período de teste gratuito de 7 dias. Por tempo limitado, quem comprar e ativar um novo iPhone, iPad, Apple TV ou Mac ganha 3 meses do Apple TV. Ele também faz parte do pacote de assinaturas da empresa, o Apple One.

NOTA DE TRANSPARÊNCIA: O MacMagazine recebe uma pequena comissão sobre vendas concluídas por meio de links deste post, mas você, como consumidor, não paga nada mais pelos produtos/serviços usando os nossos links de afiliado.

Norman Reedus is joining the series-regular cast of Apple TV’s upcoming action thriller “Disavowed.”

The project, created by Art Marcum and Matt Holloway (Iron Man, Uncharted), stars James Marsden as legendary CIA case officer Brad Griffin. Griffin is abruptly fired in the middle of a global hunt for an elusive assassin who killed his colleague. Disgraced and cut off from the intelligence world, he decides to pursue the $15 million federal bounty on the assassin’s head. Reedus’ character has not been revealed.

The series comes from Apple Studios. Marcum and Holloway executive produce alongside Tom Spezialy, Michelle MacLaren, Rebecca Hobbs, and Marsden. Blue Marble Pictures (Pachinko) produces, with Theresa Kang and Caroline Garity also serving as executive producers. MacLaren (The Morning Show, Breaking Bad) will direct the first two episodes and executive produce with Hobbs under her overall deal with Apple TV.

Reedus is best known for playing Daryl Dixon across 11 seasons of AMC’s The Walking Dead and the spinoff The Walking Dead: Daryl Dixon, which is set to conclude after its upcoming fourth season. He also starred as Murphy MacManus in The Boondock Saints and its sequel, and is in pre-production on a third installment as star and executive producer. Recent credits include Takashi Miike’s untitled Kyoto project; he next appears in Mark Heyman’s Pendulum.

MacDailyNews Note: Apple TV is available on the Apple TV app in over 100 countries and regions, on over 1 billion screens, including iPhone, iPad, Apple TV 4K, Apple Vision Pro, Mac, popular smart TVs from Samsung, LG, Sony, VIZIO, TCL and others, Roku and Amazon Fire TV devices, Chromecast with Google TV, PlayStation and Xbox gaming consoles, and at tv.apple.com, for $12.99 per month with a seven-day free trial for new subscribers. For a limited time, customers who purchase and activate a new iPhone, iPad, Apple TV 4K or Mac can enjoy three months of Apple TV for free.

---

‎
Please help support MacDailyNews — and enjoy subscriber-only articles, comments, chat, and more — by subscribing to our Substack: macdailynews.substack.com. Thank you!

Support MacDailyNews at no extra cost to you by using this link to shop at Amazon.

The post Norman Reedus joins James Marsden in Apple TV action thriller series ‘Disavowed’ appeared first on MacDailyNews.

The price of saving a newborn’s life can extend far beyond the hospital walls. A new analysis published in the Journal of Perinatology is drawing attention to a largely invisible consequence of neonatal intensive care: the direct medical out-of-pocket costs paid by families. The study, led by researchers Gorka, Profit and Phibbs, examines who carries the greatest financial burden during a neonatal intensive care unit admission and investigates how structural conditions may shape those costs.

Neonatal intensive care is among the most technologically advanced forms of medicine. Infants in NICUs may require mechanical ventilation, incubators that regulate temperature and humidity, continuous heart and oxygen monitoring, intravenous nutrition, specialized medications and repeated laboratory testing. These interventions can be lifesaving, particularly for babies born extremely prematurely or with serious medical complications. Yet the financial consequences of receiving this care are not experienced equally by every household, even when families receive treatment in the same health-care system.

The researchers’ focus is direct medical out-of-pocket spending: the money families must pay themselves for medical services connected to a NICU admission. This can include deductibles, copayments, coinsurance and other forms of cost sharing that remain after insurance has paid its portion. Unlike the total hospital charge or the amount reimbursed by an insurer, out-of-pocket cost reflects the portion that reaches a family’s own budget. For households already coping with an unexpected high-risk birth, even relatively small individual charges can accumulate rapidly.

The study is designed not only to document these expenses, but also to explore the structural forces behind differences in cost burden. In health economics, structural contributions refer to the way institutions and systems distribute risk and resources. Insurance design, employment-linked coverage, household income, geographic location, hospital characteristics and access to public assistance can all affect how much a family ultimately pays. Two infants with similar clinical needs may therefore generate very different financial experiences for their parents, depending on the architecture of coverage surrounding them.

That distinction matters because the effects of a NICU admission are not limited to the newborn’s medical condition. Parents may need to travel long distances to reach a specialized hospital, arrange accommodation near the facility, pay for transportation or meals, and take unpaid leave from work. These expenses may not always appear in estimates of direct medical out-of-pocket costs, but they can intensify the economic shock associated with a prolonged admission. The medical bill is only one component of the broader financial strain that can accompany neonatal illness.

A central question raised by the analysis is whether the families with the fewest financial resources are also the ones most exposed to high cost sharing. A payment that is manageable for a high-income household may consume a substantial share of a lower-income family’s monthly budget. Economists often describe this pattern as a disproportionate cost burden: the absolute amount paid may not be the highest, yet the payment represents a greater fraction of household resources. This distinction can reveal inequities that remain hidden when researchers look only at average dollar amounts.

The findings are expected to be relevant to health-policy debates about medical debt, insurance protection and the financial consequences of premature birth. If structural factors account for meaningful differences in family payments, reducing inequality may require more than improving clinical care. Potential responses could include limits on neonatal cost sharing, stronger protections against unexpected bills, expanded eligibility for public coverage and assistance with transportation or family support services. The analysis may also help hospitals and policymakers identify families at risk of financial hardship while an infant is still receiving care.

The issue has significance beyond individual hospitalizations because NICU care can influence a family’s financial stability long after discharge. Parents may face follow-up appointments, medications, developmental assessments and specialist care for children who experienced complications of prematurity or serious illness. Medical expenses can overlap with reduced work hours, job loss or the need for one parent to become a full-time caregiver. A short period of intensive treatment can therefore produce a long economic aftershock, particularly when families lack savings or paid leave.

By placing family payments at the center of neonatal research, Gorka, Profit and Phibbs emphasize a dimension of NICU care that is often absent from clinical success measures. Survival, complications and length of stay remain essential indicators, but they do not fully describe the experience of families navigating intensive care. Understanding who pays the most, why they pay it and how those payments relate to broader social structures could help redefine quality in neonatal medicine. The study’s message is potentially viral because it connects cutting-edge life-saving technology with a simple but consequential question: when medicine saves a baby, how much of the cost is left for the family to survive?

Subject of Research: Direct medical out-of-pocket costs of neonatal intensive care admissions and structural factors contributing to differences in financial burden among NICU families.

Article Title: Who pays the most for neonatal intensive care? An analysis of the out-of-pocket cost burden borne by NICU families

Article References: Gorka, N., Profit, J. & Phibbs, C.S. “Who pays the most for neonatal intensive care? An analysis of the out-of-pocket cost burden borne by NICU families.” Journal of Perinatology (2026). https://doi.org/10.1038/s41372-026-02869-6

Image Credits: AI Generated

DOI: 10.1038/s41372-026-02869-6

Keywords: neonatal intensive care, NICU, out-of-pocket costs, medical expenses, health-care inequality, premature birth, financial burden, insurance, neonatal health, health policy

According to an exclusive report from Deadline’s Nellie Andreeva, Apple TV is developing “Bad News Dads,” a half-hour comedy starring and executive produced by James Marsden. The project comes from “You’re the Worst” creator Stephen Falk, alongside Berlanti Productions and Warner Bros. Television, where Greg Berlanti holds an overall deal.

Based on the upcoming novel by Adam Frost, the series follows an inept men’s recreational baseball league. When one player’s wife dies in a suspicious accident, friendship-starved Ben (played by Marsden) rallies two teammates for an often-misguided investigation into what they increasingly believe was murder. While the title and baseball setting nod to “The Bad News Bears,” the story is an original concept with no direct connection to the classic sports film.

Falk, Marsden, and Frost executive produce with Greg Berlanti, Sarah Schechter, Leigh London Redman, and Robbie Rogers for Berlanti Productions. Frost’s novel is scheduled for publication on April 6, 2027, by Simon & Schuster/Atria/Emily Bestler Books.

The project continues Apple TV’s interest in mystery-comedy fare, a genre boosted by series like “The Afterparty” and Hulu’s “Only Murders in the Building.” It also extends Marsden’s recent work with the streamer: he recently appeared in “Your Friends & Neighbors” and stars in and executive produces the upcoming action thriller “Disavowed.” Marsden, known for alternating between drama and comedy (with Emmy nominations for both “Paradise” and “Jury Duty”), next reprises Cyclops in “Avengers: Doomsday.”

Falk, whose other credits include Apple TV’s “Hello Tomorrow!,” Netflix’s “Orange Is the New Black,” and Showtime’s “Weeds,” also has a “Hit Man” series inspired by the Glen Powell film in development at Netflix. Berlanti Productions has multiple projects advancing elsewhere, including series at Amazon MGM Studios and Disney+.
‎
MacDailyNews Note: Apple TV is available on the Apple TV app in over 100 countries and regions, on over 1 billion screens, including iPhone, iPad, Apple TV 4K, Apple Vision Pro, Mac, popular smart TVs from Samsung, LG, Sony, VIZIO, TCL and others, Roku and Amazon Fire TV devices, Chromecast with Google TV, PlayStation and Xbox gaming consoles, and at tv.apple.com, for $12.99 per month with a seven-day free trial for new subscribers. For a limited time, customers who purchase and activate a new iPhone, iPad, Apple TV 4K or Mac can enjoy three months of Apple TV for free.

---

‎
Please help support MacDailyNews — and enjoy subscriber-only articles, comments, chat, and more — by subscribing to our Substack: macdailynews.substack.com. Thank you!

Support MacDailyNews at no extra cost to you by using this link to shop at Amazon.

The post James Marsden to star in Apple TV comedy ‘Bad News Dads’ from Stephen Falk and Berlanti Productions appeared first on MacDailyNews.

Chegou hoje ao catálogo do Apple Arcade o jogo Madden NFL 27 Arcade Edition, da EA Sports, simultaneamente ao começo da temporada da liga de futebol americano. O título é, segundo a Apple, pensado especialmente para o seu serviço.

O jogo é uma versão completa de Madden, a série de jogos da EA dedicada à NFL. Sem anúncios ou compras dentro do aplicativo, o game inclui os modos Franquia e Jogo Rápido, cujas classificações se baseiam nas avaliações reais de desempenho dos jogadores da liga.

O modo Franquia conta com um sistema de histórias semanais, colocando o jogador no papel de gerente geral, responsável por conduzir a equipe por narrativas que evoluem ao longo da temporada, conquistar a torcida e formar uma equipe campeã. O jogo possui suporte a controle no iPhone, iPad, Mac e Apple TV.

Além dele, Retro Bowl College+, jogo retrô feito em pixel art, também chegou hoje ao Apple Arcade. Nele, os jogadores assumem o papel de técnico em uma das 250 equipes universitárias, podendo se consagrar como um nome vitorioso.

O Apple Arcade conta com mais de 200 títulos no acervo (livres de propagandas ou compras internas), os quais podem ser acessados por até cinco membros de um Compartilhamento Familiar em iPhones, iPads, Macs, Apple TVs e/ou Apple Vision Pros. O serviço de jogos custa R$14,90 por mês e também faz parte do pacote de assinaturas da empresa, o Apple One.

NOTA DE TRANSPARÊNCIA: O MacMagazine recebe uma pequena comissão sobre vendas concluídas por meio de links deste post, mas você, como consumidor, não paga nada mais pelos produtos/serviços usando os nossos links de afiliado.

The Biden administration took steps to shield workers from extreme temperatures. The Trump administration is taking a gentler approach with employers.

© Allison Joyce/Agence France-Presse — Getty Images

The Biden administration took steps to shield workers from extreme temperatures. The Trump administration is taking a gentler approach with employers.

The first U.S. attempt at reopening a shuttered reactor has been held back by run-down equipment and a lack of planning.

Em sua rede social (a Truth Social), o presidente dos Estados Unidos, Donald Trump, afirmou que investigará as multas cobradas pela União Europeia contra empresas de tecnologia americanas (como a Apple, a Amazon, o Google e a Meta) acusadas pelo bloco de terem violado a Lei dos Mercados Digitais (Digital Markets Act, ou DMA).

Na declaração, Trump prometeu reverter as penalidades financeiras aplicadas às empresas estadunidenses sancionando tarifas contra a UE. Ele também aproveitou a oportunidade para alfinetar o ex-presidente do país, Joe Biden:

A União Europeia atacou de novo e, como de costume, mirou diretamente nas GRANDES empresas americanas! Depois de multar a Apple, sem motivo aparente, em US$15 bilhões, a Meta em US$3 bilhões, a Amazon em US$2,5 bilhões, e muitas outras, nós acabamos de ser informados que o Google, um grupo fantástico e realmente avançado, acabou de receber outra multa de US$1 bilhão, sem explicação. Isso leva o total do Google para mais de US$18 bilhões!

Essa prática ilegal e altamente discriminatória começou nesses níveis elevados durante o primeiro ano da administração do dorminhoco Joe Biden, mas não continuará durante a administração Trump.

Os Estados Unidos da América não são um “COFRINHO” da Europa, e nós não vamos permitir que sejam!

Que esta VERDADE sirva para representar que vamos iniciar imediatamente uma investigação da Seção 301 ¹Lei americana de comércio que investiga práticas tributárias ou sanções injustas de outros países contra os EUA. sobre essa prática de “ROUBAR” empresas americanas e, por consequência, o contribuinte americano.

A União Europeia vai pagar caro por essa conduta ilegal e altamente antiética, sobre a qual venho alertando-os de maneira consistente. As penalidades serão inteiramente revertidas e, como esperamos, TARIFAS substanciais serão aplicadas contra eles assim que possível. Fiquem ligados!

Presidente DONALD J. TRUMP

Não é a primeira vez que o mandatário dos EUA critica a maneira como a UE penaliza as empresas americanas: em 2025, ainda recém-empossado, ele não apenas criticou essas práticas, como alegou que as multas eram, na verdade, pretextos para uma retaliação tributária e “injusta”.

Vale lembrar que o segundo mandato de Trump foi endossado de maneira reputacional e monetária por praticamente todas as empresas citadas na declaração — especialmente o CEO ²Chief executive officer, ou diretor executivo. da Apple, Tim Cook, que ajudou a financiar a cerimônia de inauguração do seu governo.

via MacRumors

Notas de rodapé

• 1
  Lei americana de comércio que investiga práticas tributárias ou sanções injustas de outros países contra os EUA.
• 2
  Chief executive officer, ou diretor executivo.

The dunes sagebrush lizard, found only in the oil-rich Permian Basin, was classified as endangered two years ago.

De acordo com informações do Deadline, o Apple TV escalou os atores Corey Stoll (“Homem-Formiga”), Ralph Ineson (“Quarteto Fantástico: Primeiros Passos”) e Nyasha Hatendi (“O Canto do Cisne”) para o spinoff de “Monarch — Legado de Monstros” (“Monarch: Legacy of Monsters”), projeto anunciado no ano passado.

Os três juntam-se a Millie Brady, Pilou Asbæk e Wyatt Russell. Este último, vale recordar, estrelará a produção como o jovem Lee Shaw, personagem que é interpretado por seu pai (Kurt Russell) na série original.

Na trama, Shaw é retratado como um agente americano que embarca em uma missão secreta (em 1984) para impedir que soviéticos liberem um Titã “horrível, grande o suficiente para destruir os Estados Unidos” e mudar os rumos da Guerra Fria.

Os personagens que serão interpretados pelos três novos atores ainda não foram divulgados pelo Apple TV — por enquanto, o que sabemos é que eles serão papéis regulares na futura produção.

Joby Harold será showrunner e também produtor executivo ao lado de Russell, Tory Tunnel, Chris Black, Kyle Bradstreet, Alex Boden, Max Borenstein, Andy Goddard, Hiro Matsuoka e Takemasa Arita.

O Apple TV está disponível no aplicativo Apple TV em mais de 100 países e regiões, seja em iPhones, iPads, Apple TVs, Macs, dispositivos Android, smart TVs ou online — além de também estar em aparelhos como Roku, Amazon Fire TV, Chromecast com Google TV, consoles PlayStation e Xbox. O serviço custa R$29,90 por mês, com um período de teste gratuito de 7 dias. Por tempo limitado, quem comprar e ativar um novo iPhone, iPad, Apple TV ou Mac ganha 3 meses do Apple TV. Ele também faz parte do pacote de assinaturas da empresa, o Apple One.

NOTA DE TRANSPARÊNCIA: O MacMagazine recebe uma pequena comissão sobre vendas concluídas por meio de links deste post, mas você, como consumidor, não paga nada mais pelos produtos/serviços usando os nossos links de afiliado.

The Trump administration wants to roll back some Biden-era restrictions on smog-causing emissions from heavy-duty vehicles.

© Justin Sullivan/Getty Images